CB-011 is an investigational allogeneic anti-BCMA CAR-T cell therapy being developed by Caribou Biosciences using its proprietary CRISPR-Cas12a chRDNA genome-editing platform. The product incorporates four genome edits intended to improve safety, persistence, and resistance to immune rejection. These include insertion of a BCMA-targeted CAR construct, knockout of the TRAC gene to reduce graft-versus-host disease risk, knockout of B2M to decrease host T-cell-mediated rejection, and insertion of a B2M-HLA-E fusion protein to mitigate natural killer (NK) cell-mediated clearance. Collectively, these modifications form the basis of the therapy’s "immune cloaking" strategy.

The ongoing Phase I CaMMouflage trial is evaluating CB-011 in patients with RRMM who have previously received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. The study includes dose-escalation and expansion cohorts designed to establish the recommended Phase II dose while assessing safety, expansion kinetics, and anti-myeloma activity.

A total of 48 patients received CB-011. The median age was 68.5 years (49–84). Patients received a median of 4 prior lines of therapy (3–11), and 17% received prior BCMA-targeted therapy. 56% of patients had high-risk cytogenetics, and 35% had extramedullary disease.

Efficacy Outcomes-

• For BCMA-naïve patients who received the recommended dose for expansion of CB-011 (n = 12), the ORR was 92%, and the CR rate was 75%.

• At a median follow-up of 8.3 months, 7/12 (58%) patients were in a VGPR or better at ≥6 months.

• Of the MRD-evaluable patients, 10/11 (91%) achieved MRD negativity at a 10–5 threshold. 

• CB-011 exhibits a central memory CD8 T cell phenotype at the peak of expansion. 

• CB-011 expansion directly correlated with clinical responses and was higher in patients treated with 500 cyclophosphamide compared with 300 cyclophosphamide lymphodepletion. 

• Rapid recovery of endogenous T and NK cells was observed, with endogenous B cells recovering within 6 months regardless of clinical response. 

Safety Outcomes-

• In patients who received the 500 cyclophosphamide lymphodepletion regimen (n = 35), infections occurred in 49% of patients (14%, Grade ≥3), CRS occurred in 31% of patients (3%, Grade ≥3), ICANS occurred in 9% of patients (no Grade ≥3), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome occurred in 9% of patients (3%, Grade ≥3), and prolonged Grade ≥3 cytopenias occurred in 33% of patients. 

• No cases of GvHD, immune effector cell-associated enterocolitis, Parkinsonism, or cranial nerve palsies were observed at any dose level. 

• One Grade 4 event of Guillain-Barré syndrome (GBS) occurred and is resolving. 

• Three deaths occurred [pneumonia (unrelated), RSV (unrelated), ICAHT (related)], and have resulted in prophylactic measures/early intervention being implemented.

KOL Insights-

“The correlation between CAR-T expansion and clinical benefit highlights the importance of optimizing both cellular engineering and lymphodepletion strategies in next-generation off-the-shelf therapies.”– Expert Opinion

“Achieving deep clinical responses without evidence of graft-versus-host disease represents a key milestone in the evolution of allogeneic CAR-T therapy. The results support the feasibility of developing effective off-the-shelf cellular therapies and underscore the potential of this approach to expand patient access to CAR-T treatment.”– Expert Opinion

Conclusion-

Multiple myeloma remains an incurable plasma-cell malignancy characterized by repeated relapses and progressively shorter treatment responses with each subsequent line of therapy. Although BCMA-directed autologous CAR-T therapies have transformed outcomes in relapsed/refractory disease, manufacturing complexity, treatment delays, and limited accessibility continue to restrict broader patient access.

The Phase I CaMMouflage study demonstrates that CB-011, an immune-cloaked allogeneic BCMA-directed CAR-T therapy, can induce deep responses in a heavily pretreated and biologically high-risk multiple myeloma population while maintaining a manageable safety profile. The absence of graft-versus-host disease and the strong activity observed at the recommended expansion dose provide early clinical support for this novel off-the-shelf approach. As enrollment continues into the expansion phase, CB-011 may emerge as an important next-generation cellular therapy designed to broaden access to CAR-T treatment while preserving efficacy in RRMM.